Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Key Points

• Wells Fargo & Company raised its price target for Insmed from $140 to $171, indicating a potential upside of 17.69% from the current stock price and maintaining an "overweight" rating.
• Insmed's stock has received multiple upgrades from analysts, with a consensus target price of $134.79 and 16 analysts rating it as a buy.
• Despite a reported loss of ($1.70) EPS, Insmed's revenue for the quarter increased by 18.9% year-over-year, totaling $107.42 million, exceeding analyst expectations.

Insmed (NASDAQ:INSM - Get Free Report) had its price objective boosted by analysts at Wells Fargo & Company from $140.00 to $171.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price target suggests a potential upside of 17.69% from the company's current price.

Other analysts also recently issued research reports about the stock. Bank of America upped their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research note on Wednesday, August 20th. The Goldman Sachs Group upped their price objective on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Leerink Partners increased their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. Finally, HC Wainwright increased their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $134.79.

Insmed Trading Up 6.8%

INSM opened at $145.30 on Wednesday. The firm's fifty day moving average is $112.13 and its two-hundred day moving average is $88.41. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed has a twelve month low of $60.40 and a twelve month high of $146.52. The firm has a market cap of $30.71 billion, a PE ratio of -25.45 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period last year, the business posted ($1.94) EPS. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Buying and Selling

In other news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the sale, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $30,035,841.60. The trade was a 2.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 512,927 shares of company stock valued at $51,227,401 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the period. Elequin Capital LP bought a new position in Insmed during the 4th quarter valued at about $28,000. ORG Partners LLC lifted its stake in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank bought a new position in shares of Insmed in the 2nd quarter worth approximately $28,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Insmed in the 2nd quarter worth approximately $33,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.